Shopping Cart
- Remove All
- Your shopping cart is currently empty
SCH772984 HCl is a selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors, with IC50s of 4 and 1 nM, respectively. SCH772984 HCl has nanomolar cellular potency in tumor cells with mutations in BRAF, NRAS, or KRA
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $95 | Backorder | |
5 mg | $135 | Backorder | |
10 mg | $198 | Backorder |
Description | SCH772984 HCl is a selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors, with IC50s of 4 and 1 nM, respectively. SCH772984 HCl has nanomolar cellular potency in tumor cells with mutations in BRAF, NRAS, or KRA |
Targets&IC50 | ERK2:1 nM, ERK1:4 nM |
In vitro | In LOX BRAFV600E melanoma cells, SCH772984 HCl (3, 10, 30, 100, 300 nM; 24 hours) inhibited ERK and RSK phosphorylation. SCH772984 HCl showed EC50 values less than 500 nM in approximately 88% and 49% of BRAF-mutant (n=25) or RAS-mutant (n=35) tumor lines, respectively. In SCH772984 HCl-sensitive melanoma cells, SCH772984 HCl (300 nM; 24-48hours) resulted in a G1 arrest[1]. |
In vivo | In female nude mice bearing human LOX BRAFV600E tumors, SCH772984 HCl (12.5, 25, 50 mg/kg; i.p. twice daily for 14 days) lead to 98% tumor regression at all doses. Dose-dependent antitumor activity is also observed in the KRAS-mutant pancreatic MiaPaCa model, with 36% regression at 50 mg/kg twice daily. Importantly, tumor regression is accompanied by robust inhibition of ERK phosphorylation in tumor tissue[1]. |
Molecular Weight | 624.14 |
Formula | C33H34ClN9O2 |
Smiles | O=C(NC1=CC2=C(NN=C2C3=CC=NC=C3)C=C1)[C@H]4CN(CC(N5CCN(C6=CC=C(C7=NC=CC=N7)C=C6)CC5)=O)CC4.[H]Cl |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O: 23.5 mg/mL (with gentle warming) |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.